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Abstract
Highly pathogenic avian influenza A (HPAI) H5N1 viruses are circulating among poultry populations in parts of Asia, Africa,
and the Middle East, and have caused human infections with a high mortality rate. H5 subtype hemagglutinin (HA) has
evolved into phylogenetically distinct clades and subclades based on viruses isolated from various avian species. Since 1997,
humans have been infected by HPAI H5N1 viruses from several clades. It is, therefore, important to develop strategies to
produce protective antibody responses against H5N1 viruses from multiple clades or antigenic groups. In the current study,
we optimized the signal peptide design of DNA vaccines expressing HA antigens from H5N1 viruses. Cross reactivity analysis
using sera from immunized rabbits showed that antibody responses elicited by a polyvalent formulation, including HA
antigens from different clades, was able to elicit broad protective antibody responses against multiple key representative
H5N1 viruses across different clades. Data presented in this report support the development of a polyvalent DNA vaccine
strategy against the threat of a potential H5N1 influenza pandemic.
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Introduction
The continuous spread of highly pathogenic avian influenza
Type A (HPAI) H5N1 viruses in avian species across multiple
continents and frequent reports of human H5N1 infection in China
and Southeast Asia highlight the threat of a potential flu pandemic
in the human population. At the same time, H5N1 viruses have
grown into genetically and antigentically diversified viruses. Based
on phylogenetic analysis of hemagglutinin (HA) protein gene
sequences, at least 10 clades of H5N1 viruses (clades 0–9) have been
identified [1,2,3,4,5]. Recent studies have further assigned these
viruses into four major antigenic groups (A–D) [3]. HPAI H5N1
viruses from more than one clade have caused human infection
since 1997.
A keycomponent in the global strategy to prepare for and control
any pending influenza pandemic is the development of an effective
vaccine. Several versions of inactivated as well as live attenuated
H5N1 vaccines have been tested in humans and showed an overall
good safety and immunogenicity profile mainly by using a clade 1
H5N1 virus (A/Vietnam/1203/04) as the vaccine strain per
recommendations by the World Health Organization (WHO)
[6,7,8]. Given that the majority of the world’s human population is
naı ¨ve to H5N1 influenza, two immunizations are needed to achieve
desired levels of protective immune responses against H5N1 in
contrast to the annual seasonal flu vaccine which requires only one
immunization, presumably due to the priming effects by either
exposure to circulating H1, H3 or Type B influenza viruses in
humans or history of prior seasonal flu vaccination. The likely
requirement of two immunizations in conjunction with the genetic
complexity of H5N1 viruses, as evidenced by their separation into
multiple subgroups, makes it difficult to prepare for the timely
production of a sufficient number of doses of H5N1 vaccines in the
event of an H5N1 pandemic; therefore, supplemental strategies are
needed. As shown by our previously published report [9] and
confirmed by other recent studies [10], a DNA prime-inactivated
vaccine boost is highly effective in eliciting higher protective
immune responses than using either DNA or inactivated flu vaccine
alone. Therefore, it may be possible to use DNA vaccines as the first
dose of immunization that can be given either long before the
pandemic (pre-pandemic vaccination) or shortly after the outbreak,
to reduce the burden on the production of inactivated vaccines at
the time of the outbreak. Furthermore, DNA vaccines can be
stockpiled for a long period of time, which makes this method even
more attractive.
PLoS ONE | www.plosone.org 1 December 2011 | Volume 6 | Issue 12 | e28757One key issue that needs to be analyzed for the above strategy is
the cross reactivity between DNA vaccines expressing H5 HA
antigens from different clades. It is critical to first optimize the
immunogenicity of H5 HA DNA vaccines and then to test how
much cross protection can be achieved with optimized H5 HA
DNA vaccines. In the current report, we constructed DNA
vaccines to express wild type HA antigens without mutations at the
HA1 and HA2 cleavage site from four key H5N1 strains that have
caused major human infection: HK/156/97 (clade 0), VN/1203/
04 (clade 1), Ind/5/05 (clade 2.1), and Anhui/1/05 (clade 2.3).
Rabbit sera immunized with these HA antigens were examined
for their protective antibody responses against either homologous
or heterologous H5N1 viruses. Our results demonstrated an
imperfect cross-reactivity profile for the protective antibody
responses among these four viruses. A polyvalent formulation
including three different H5 HA DNA vaccines was able to
produce broad protective antibody responses with high titers
against these key H5N1 isolates. Information learned from this
study should facilitate the selection of candidate H5N1 vaccines to
form polyvalent H5N1 DNA vaccines as part of the global strategy
to prevent and control a potential avian flu pandemic.
Results
Designs of DNA vaccines expressing different forms of
H5 HA antigens
One of the key findings from our previous study was that HA
antigens from H1 and H3 serotypes had different structure
preferences in order to elicit optimal protective antibodies [11].
Two of the HA antigen designs used in that study were also
included in the current study to identify the optimal design for the
H5 serotype HA antigens: one used the wild type HA antigen
insert (H5.wt), which has the exact same amino acid sequences
found in the natural viral isolate, and the other used a truncated
HA antigen insert (H5.dTM), which removed the transmembrane
(TM) and intracellular segments of the HA2 domain (Fig. 1). In
addition, a third HA antigen insert was created (H5.tPA), in which
a human tissue plasminogen activator (tPA) sequence replaced the
original wild type leader sequence from the HA antigen (Fig. 1).
The third HA antigen design was adopted because the H5.dTM
design also used a tPA leader sequence and the H5.tPA insert
served as a control for the H5.dTM insert to understand the role of
the tPA leader when it is incorporated as the only change in the
design from the original wild type HA antigen insert.
In order to maximize the immunogenicity of HA DNA vaccines
as shown in previous studies [9,11], HA genes used in the current
study were also codon optimized and chemically synthesized. In
addition, the HA gene sequences used in the current study express
intact HA amino acid sequences at the cleavage site between HA1
and HA2 (PQREXRRKKRQG) of HA proteins in highly
pathogenic H5N1 viruses [12,13,14]. This cleavage was shown
to be important for the pathogenesis of H5N1 viruses [12,15]. For
inactivated H5 serotype flu vaccines, these residues were removed
to improve the safety profile of such vaccines for both manufact-
uring and mass immunization purposes [7] [16,17,18].
Expression and immunogenicity of different forms of
DNA vaccines coding for the HA antigen of a 1997 H5N1
influenza Hong Kong isolate
The first set of H5 HA DNA vaccines was produced by cloning
codon optimized HA genes based on the amino acid sequences of
HA antigen from an H5N1 influenza isolate A/HongKong/156/
97, which was responsible for the first outbreak of H5N1 avian
influenza in humans in 1997, into a DNA vaccine vector [19]. The
expression of HA antigens from three different H5-HK DNA
vaccines was examined in transiently transfected 293T cells
(Fig. 2A). Regardless of whether the natural HA leader or tPA
leader was used, HA proteins expressed from two full length H5-
HK DNA vaccine constructs (HA-HK.wt and HA-HK.tPA) were
detected in cell lysate but not in the supernatant, suggesting they
are mainly cell-associated. In contrast, truncation of the C-
terminal segment, including the removal of the TM domain in the
H5-HK.dTM DNA vaccine construct, was able to significantly
increase the secretion of HA protein (detected in supernatant)
(Fig. 2A). H5-HK HA proteins expressed by all of three HA DNA
vaccine designs were able to be cleaved into HA1 and HA2
subunits (Fig. 2A).
New Zealand White (NZW) rabbits were used in the current
study to produce large quantities of sera for both binding antibody
and functional antibody analyses. Animals were immunized with
one of the three H5-HK HA DNA vaccines (individually) via gene
gun. Positive antibody responses were elicited in immunized rabbit
sera against the HK HA antigen and levels of such responses
increased with repeated immunizations while the negative control
rabbit group that received empty DNA vector did not have HA-
specific antibody responses (Fig. 2B). As measured by both temporal
and peak-level antibody responses, there was no difference in the
ability of the three forms of H5-HK HA DNA vaccines to elicit H5
HA-specific antibody responses (Fig. 2B and 2C).
However, functional antibody analyses with the rabbit anti-HA
immune sera showed a very different picture when these sera were
further analyzed by either the hemagglutination inhibition (HI) or
microneutralization (MN) assays. All three forms of H5-HK HA
DNA vaccines induced protective antibody responses against the
autologous wild type virus A/HongKong/483/97, but levels of
protective antibodieswere differentamong sera induced bydifferent
designs of H5-HK HA DNA vaccines. The DNA vaccine with the
full length HA insert under the tPA leader sequence (H5-HK.tPA)
elicited consistently higher HI and MN antibody titers when
compared to the other two forms of HK-HA inserts, the full length
HA with a natural leader sequence (H5-HK.wt), and the
transmembrane region (TM) truncated HA (H5-HK.dTM). The
differencewasstatisticallysignificant(p,0.05)between H5-HK.tPA
andH5-HK.dTM sera based on the HI assay(Fig.2D)andbetween
H5-HK.tPA and H5.HK.wt sera based on the MN assay (Fig. 2E).
Figure 1. Schematic diagram of influenza A H5 HA gene inserts
used in codon optimized DNA vaccines (A/HongKong/156/97
and A/VietNam/1203/2004), including the full length HA
antigens with natural leader sequence (H5.wt) or a human
tissue plasminogen activator (tPA) leader substituting the
natural HA leader sequence (H5.tPA) and the transmembrane/
cytoplasmic region truncated HA antigens (H5.dTM) with tPA
leader sequence. The cleavage site between HA1 and HA2 subunits
are marked. The numbers above the HA inserts denote the relevant
amino acid positions in natural HA proteins.
doi:10.1371/journal.pone.0028757.g001
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DNA vaccines coding for the HA antigen of an H5N1
isolate A/VietNam/1203/04
In order to rule out that the above finding was not only unique
to this H5N1 virus isolate from Hong Kong in 1997, similar
designs of HA inserts were produced by using a codon optimized
HA DNA gene from the H5N1 strain A/VietNam/1203/04, a
well-studied representative isolate for the H5N1 viruses [20,21].
The pattern of H5-VN HA expression was similar to that of H5-
HK HA antigens. Only cell-associated HA antigens were detected
with H5-VN.wt and H5-VN.tPA constructs in contrast to that
identified with the H5-VN.dTM, which had HA antigen
expression in both cell lysate and supernatant fractions (Fig. 3A).
Rabbits were immunized with the electroporation method as
previously reported [22]. Similar to H5-HK DNA plasmids,
binding antibody responses, as measured by ELISA, showed
similar levels among sera elicited by the three H5-VN DNA
vaccines with different HA gene insert designs (Fig. 3B). However,
functional antibodies, as measured by HI and MN antibody
analyses, revealed again that the H5-VN.tPA design induced the
highest levels of functional antibody responses (Fig. 3C and 3D). In
the case of functional antibody responses against the wild type
virus A/VietNam/1203/04, the differences between H5-VN.tPA
and the other two forms were statistically significant by both HI
and MN assays (p,0.05 or p,0.01).
In order to ensure that the difference in protective antibody
responses between sera elicited by H5-VN.wt and H5-VN.tPA was
not the result of repeated immunizations, sera collected after one
or three immunizations were also measured (Fig. 4). Pseudotyped
viruses expressing VN HA antigen were used to measure the
neutralizing antibody activities in rabbit sera with less immuniza-
tions. The strength of protective antibodies was measured at two
levels: inhibition concentrations that can block either 50% (IC50)
or 90% (IC90) of virus infection to target cells. Both measurements
showed that H5-VN.tPA-elicited rabbit sera had significantly
higher titers of neutralizing antibody activities than the wild type
H5 HA design, especially when using the more stringent IC90 as a
cut-off (p,0.05 or p,0.01) (Fig. 4).
Figure 2. Antigen expression and immunogenicity of H5-HK HA DNA vaccines. A. Western blot analysis of the expression, secretion, and
susceptibility to cleavage expressed by different H5-HK (A/HongKong/156/97) HA DNA vaccine constructs in transiently transfected 293T cell
supernatant (S) and cell lysate (L). B. Temporal serum anti-HA IgG responses in rabbits measured by ELISA at 1:5000 serum dilution against H5-HK-
dTM as coating antigen. The arrows indicate the time of gene gun-mediated DNA immunizations. Each curve represents the OD value of each group
of 3 rabbits receiving H5-HK.wt, H5-HK.tPA, H5-HK.dTM DNA vaccine or empty DNA vector as indicated. C. End titration titers of serum anti-H5-HK HA
IgG responses at two weeks after the 4
th DNA immunization from the same rabbits shown in panel B. D. The hemagglutination inhibition (HI)
antibody responses in NZW rabbit sera immunized with different designs of H5-HK HA DNA vaccines collected at 2 weeks after the 4
th DNA
immunization (DNA-4) or relevant pre-bleed sera as indicated. The HI antibody titers are shown as the geometric means for each group (3 rabbits per
group) with standard deviations against H5N1 A/HongKong/483/97 virus. E. Neutralizing antibody (NAb) responses in NZW rabbit sera immunized
with different designs of H5-HK HA DNA vaccines collected at 2 weeks after the 4
th DNA immunization (DNA-4) or relevant pre-bleed sera as
indicated. NAb titers against H5N1 A/HongKong/483/97 virus infection to MDCK cells are shown as the geometric means from each group (3 rabbits
per group) with standard deviation. The statistical differences between each testing groups are determined and P values less than 0.05 or 0.01 are
indicated.
doi:10.1371/journal.pone.0028757.g002
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expressed by different forms of H5-VN HA DNA vaccines
Additional studies were conducted to ask if glycosylation of HA
has been affected with the use of a different leader sequence which
may influence the immune responses. Our previous study with a
hepatitis B surface antigen suggested that post-translational
modifications including glycosylation may affect the immunoge-
nicity of DNA vaccine delivered antigens [23]. The Asn (N)-linked
glycosylation of influenza HA proteins are essential for virus
infectivity and vaccine immunogenicity [24,25]. Based on sequence
analysis, there are 8 to 9 N-linked glycosylation sites (Asn-X-Ser/
Thr) in H5N1 HA proteins. We next investigated whether the HA
antigens expressed by different designs of H5 HA inserts in the
above DNA vaccinations have similar levels of N-linked glycosyl-
ation. The HA antigens expressed in 293T cell lysate transfected
with the H5-VN.wt, H5-VN.tPA or H5-VN.dTM DNA vaccines
and HA antigen expressed in the 293T cell supernatant transfected
with the H5-VN.dTM DNA vaccine were analyzed for their
susceptibility to PNGase treatment, which can cleave any type of N-
linked sugar including complex oligosaccharide structures resulting
from the maturation of high mannose moieties during transport of
the glycoprotein through the Golgi.
Treatment with PNGaseF allowed for the removal of N-linked
glycosylations, as shown by the reduction of apparent molecular
weight of HA0, HA1, and HA2 species in Western blot analysis for
HA proteins expressed in cells transfected by these H5-VN HA
DNA vaccines (Figure S1). The molecular weight reduction
patterns for HA0, HA1, and HA2 antigens were the same between
cells transfected by H5-VN.wt and H5-VN.tPA DNA vaccines,
suggesting that HA antigens expressed by these two HA DNA
vaccines were similarly glycosylated. A smaller molecular weight
Figure 3. Antigen expression and immunogenicity of H5-VN HA DNA vaccines. A. Western blot analysis of the expression, secretion, and
susceptibility to cleavage expressed by different H5-VN (A/VietNam/1203/2004) HA DNA vaccine constructs in transiently transfected 293T cell
supernatant (S) and cell lysate (L). B. End titration titers of serum anti-H5-VN HA IgG responses at two weeks after the 4
th DNA immunization from
rabbits immunized with differently designed H5-VN DNA vaccines against H5-VN.dTM as coating. C. The hemagglutination inhibition (HI) antibody
responses in NZW rabbit sera immunized with different designs of H5-VN HA DNA vaccines collected at 2 weeks after the 4
th DNA immunization
(DNA-4) or relevant pre-bleed sera as indicated. The HI antibody titers are shown as the geometric means for each group (3 rabbits per group) with
standard deviations against H5N1 A/VietNam/1203/04 virus. D. Neutralizing antibody (NAb) responses in NZW rabbit sera immunized with different
designs of H5-VN HA DNA vaccines collected at 2 weeks after the 4
th DNA immunization (DNA-4) or relevant pre-bleed sera as indicated. NAb titers
against H5N1 A/VietNam/1203/04 virus infection to MDCK cells are shown as the geometric means from each group (3 rabbits per group) with
standard deviation. The statistical differences between each testing groups are determined and P values less than 0.05 or 0.01 are indicated.
doi:10.1371/journal.pone.0028757.g003
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VN.dTM DNA vaccine, presumably due to the truncated size of
HA2 domain in this particular HA insert design; however,
PNGaseF treatment also led to a proportional reduction of
molecular weight for truncated HA2 protein in both supernatant
and cell lysate preparations. The only unique finding is that the
cell-associated HA antigens in H5-VN.dTM transfected cells
showed a high level of heterogeneity and a small portion of the
HA1 proteins was not fully deglycosylated by PNGaseF treatment,
reflecting the continued presence of different forms of glycosylated
HA proteins in H5-VN.dTM transfected cells. Otherwise, the
overall glycosylation pattern, as probed by deglycosylation treat-
ment, was very similar among HA antigens produced by three
different types of H5 HA DNA vaccines.
Cross-protective antibody responses induced by
individual DNA vaccines expressing HA antigens from
key H5N1 viral isolates
Based on the above results, additional HA DNA vaccines with
the HA.tPA insert design were produced by using codon optimized
HA genes that encode the HA proteins from H5N1 viral strains
A/Anhui/1/2005 and A/Indonesia/5/2005, both have caused
human infection in recent years [26,27]. Given the circumstance
that H5N1 influenza antigen drifts have occurred since the first
human outbreak in Hong Kong in 1997, it would be important to
determine if H5 HA vaccines developed based on H5N1 viruses
isolated at different epidemic time points can induce cross
antibody responses against other H5N1 viruses.
One set of experiments was conducted to understand the cross
protection between paired H5N1 HA antigens. Rabbits were
immunized with individual H5-HK.tPA, H5-VN.tPA, and H5-
AH.tPA DNA vaccines and rabbit immune sera were examined
for HA antigen-specific antibody responses. H5 HA-specific
antibody responses against H5 HA antigens from different viruses
were analyzed by ELISA and the potential cross-protective anti-
body responses against different H5N1 viruses were evaluated by
HI and MN assays.
H5-HK (A/HK/156/97), a clade 0 H5N1 isolate, and H5-VN
(A/VN/1203/04), a clade 1 H5N1 isolate, represent H5N1 viruses
isolated from the first human outbreak in Hong Kong in 1997 and
a subsequent outbreak in Vietnam in 2004, respectively. Results
shown in Fig. 5 indicate that H5-HK.tPA DNA vaccine-immunized
rabbit sera showed high antibody responses recognizing both the
autologous H5-HK HA antigen and the heterologous H5-VN HA
antigen. However, the HA-specific IgG titers against the autologous
H5-HK antigen were higher than those observed against the
heterologous H5-VN antigen (p,0.05). Conversely, the H5-
VN.tPA DNA vaccine elicited high level HA-specific IgG responses
against autologous H5-VN and heterologous H5-HK HA antigens
although the overall titers against its autologous H5-VNHAantigen
may be higher (not statistically significant).
Protective HI and MN antibody responses induced by H5-
HK.tPA and H5-VN.tPA DNA vaccines were further compared
against either A/HK/483/97 or A/VN/1203/04 wild type
viruses (Fig. 5). HI and MN titers were present in both HK.tPA
and H5-VN.tPA DNA vaccine-immunized rabbit sera against
Figure 4. Neutralizing antibody responses detected by the pseudotyped virus system expressing the H5 VN-HA antigen. Early time
point sera, at 2 weeks after either one (DNA-1) or three (DNA-3) DNA immunizations, were collected from the same groups of rabbits included in
Fig. 3. A. Neutralizing antibody titers measured at 50% inhibition (IC50) of virus infection to target cells. B. Neutralizing antibody titers measured at
90% inhibition (IC90) of virus infection to target cells. Data shown are the geometric mean titers of each group with standard deviations. The
statistical differences between each testing groups are determined and P values less than 0.05 or 0.01 are indicated.
doi:10.1371/journal.pone.0028757.g004
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degree of strain specificity. Statistically significant higher HI and
MN titers were observed in H5-HK.tPA DNA vaccine-immunized
rabbit sera against the autologous virus, A/HK/483/97, when
compared to responses observed against the heterologous virus, A/
VN/1203/04 (p,0.05). Similarly, the H5-VN.tPA DNA vaccine
induced much higher HI and MN responses against its autologous
virus, A/VN/1203/04, compared to the heterologous virus, A/
HK/483/97 (p,0.05).
Similar analysis was conducted with rabbit immune sera elicited
by H5-VN and H5-AH HA DNA vaccines (Fig. 6). H5-AH (A/
Anhui/1/05), a clade 2.3 H5N1 isolate, represents the H5N1 virus
isolated from a human outbreak in China in 2005 [26]. The cross
reactivity between H5-VN and H5-AH immune sera and viruses
was very similar to that observed above between H5-HK and H5-
VN immune sera and viruses. For binding antibody responses,
H5-VN rabbit immune sera had significantly higher recognition
to its autologous H5-VN HA antigen than the heterologous H5-
AH HA antigen (p,0.05). H5-AH rabbit immune sera elicited
higher antibody responses recognizing the autologous H5-AH HA
antigen than the heterologous H5-VN HA antigen (not statistically
significant) (Fig. 6). For functional antibodies, both HI and MN
analyses showed preference for H5-VN and H5-AH rabbit im-
mune sera against their respective autologous wild type viruses, A/
VN/1203/04 and A/Anhui/1/05 (p,0.05 or p,0.01) (Fig. 6).
Cross-protection by a polyvalent DNA vaccine
formulation expressing HA antigens from three
representative H5N1 viral isolates
The above results indicate that while antibody responses against
one H5N1 HA antigen or virus may well cross-react with another
H5N1 HA antigen or virus, the levels of antibody responses
against the autologous antigen or virus were always higher. Given
the uncertainty regarding which H5N1 virus may ultimately cause
a pandemic H5N1 outbreak, it is important to develop a vaccine
strategy that can maximize the protection efficacy against a wide
spectrum of H5N1 viruses from different clades (or subtypes). It is
possible that a consensus HA antigen, or a structurally-optimized
HA antigen design, can cover different H5N1 viruses at various
levels of protective efficacy but there is no actual data showing that
such HA antigen can achieve the maximum protective antibody
responses against several H5N1 viral isolates from different clades.
One alternative approach is to produce a polyvalent HA
formulation by including multiple H5N1 HA DNA vaccines in one
injection to produce an immune sera that can induce the highest
antibody response against a wide range of H5N1 viral isolates. For
this purpose, we have tested one such polyvalent HA DNA vaccine
formulation by injecting rabbits with three H5 HA DNA vaccines:
H5-VN.tPA, H5-AH.tPA, and H5-IN.tPA DNA vaccines. A H5-
IN.tPA DNA vaccine was produced expressing the HA antigen
from another key H5N1 viral isolate, A/Indonesia/5/2005, a
clade 2.1 H5N1 isolate. Rabbits in other groups received only one
H5 HA DNA vaccine (monovalent). Functional antibody analysis
was conducted against pseudotyped viruses expressing different
individual H5 HA and N1 antigens.
The pseudotyped virus system, developed in recent years and
widely used in leading influenza studies, provides high sensitivity in
detecting functional antibody responses against influenza HA
antigens, and at the same time, eliminates the influence of other
influenzaviral gene productssincea commonviral backbone isused
for different HA pseudotyped viruses [28,29]. It is an ideal system as
a high-throughput assay for multiple serum samples against a wide
range of viruses. As shown in Fig. 6, rabbit sera elicited by either the
3-valent HA DNA vaccine formulation (H5-VN+H5-AH+H5-IN)
or the monovalent H5 HA DNA vaccines (HK, VN, AH, and IN)
were tested for their antibody responses against three pseudotyped
viruses expressing H5-VN, H5-AH, or H5-IN HA antigens. The
matched monovalent rabbit sera consistently showed the highest
functional antibody responses against autologous pseudotyped
viruses (Fig. 7A–7C). However, the 3-valent serum was the only
one that showed high level antibody responses against all three
pseudotyped viruses while one non-matched monovalent rabbit
serum could neutralize one or two viruses but not all three, further
confirming the hypothesis that a polyvalent HA formulation is
capable of protect against multiple H5N1 viruses.
Discussion
According to phylogenetic analysis, H5N1 viruses can be
divided into 10 clades (0–9). Since 1997, humans have mainly
Figure 5. Levels and specificity of anti-HA IgG (upper panel),
hemagglutination inhibition (HI, middle panel), and neutraliz-
ing (NAb, lower panel) antibody responses elicited by H5-HK
and H5-VN HA DNA vaccines in rabbits immunized with H5-
HK-tPA and H5-VN-tPA (3 rabbits/group), respectively, at two
weeks after the 4
th DNA immunization. Peak serum level anti-H5
HA IgG responses as measured by ELISA against H5-HK-dTM or H5-VN-
dTM antigens. HI antibody titers and NAb were detected against H5N1
A/HongKong/483/97 or A/VietNam/1203/04 virus, respectively. Neutral-
izations against wild type H5N1 viruses were performed in MDCK cells.
doi:10.1371/journal.pone.0028757.g005
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there have also been reports of infection by clade 7 virus [5]. Clade
2 is the most complicated in its genetic evolution and has been
further divided into five subclades (2.1 to 2.5). In the current study,
we have selected HA antigens from one clade 0 virus (A/
HongKong/156/97), one clade 1 virus (A/VietNam/1203/2004),
two clade 2 viruses (A/Indonesia/5/2005, clade 2.1; and A/
Anhui/1/2005, clade 2.3) [3].
While progress has been made in reducing the number of
required immunizations during vaccination with inactivated H5N1
vaccines by incorporating various adjuvants into the vaccine
formulations, a major next-step for H5N1 vaccine research is to
determine to what degree the immunity elicited by one H5 avian
influenza vaccine (currently, many candidate H5N1 vaccines were
developed based on a clade 1 virus (A/VietNam/1203/2004)) can
cross-protect against H5N1 viruses from other clades. Unlike
humanType A influenzaviruses(H1orH3serotypes), any potential
pandemic caused by an H5N1 virus will be of avian origin and, in
theory, any of the current known H5N1 avian viruses may jump to
the human population leading to the next pandemic. Therefore, a
systemic examination on the cross-protection among HA antigens
from different clades is needed for strategic planning to determine
whether more than one H5N1 vaccine is needed based on the
analysis of protection profiles, and if so, what particular viral strains
should be selected to provide the maximum breadth of protection.
DNA vaccination is an attractive strategy to provide relatively
quick and straightforward production of vaccines against an
influenza pandemic when the demand for such vaccines suddenly
increases. However, a key issue surrounding the use of DNA
vaccines is their low immunogenicity in humans. In recent years,
the success of the prime-boost strategy has greatly enhanced the
utility of DNA vaccination for future human applications [10,30].
At the same time, optimization of the design of antigen inserts
based on the uniqueness of each antigen (a process of ‘‘antigen
engineering’’) [31,32] can also play a key role.
Results included in the current report indicated that the tPA
leader sequence and the C-terminal transmembrane domain/
cytoplasmic region of H5 HA both contribute to better functional
antibody responses in H5.tPA DNA vaccines when compared to
H5.wt and H5.dTM DNA vaccines. The above findings were
different from our previous results on protective antibody
responses induced by differently designed flu H1 and H3 HA
DNA vaccines [11]. In this previous study, only the full length
H1.wt but not transmembrane truncated H1.dTM induced high
level HI and MN responses against H1 virus while both the full
length H3.wt and truncated H3.dTM induced similar HI and MN
responses against H3 virus [11]. These results provide a strong
indication that the HA antigens from different influenza A
subtypes (H1, H3 and H5) may have different preferences for
antigen structure designs in order to generate optimal protective
antibody responses.
Studies were conducted in this report to identify the mechanism
responsible for better protective antibodies in rabbit immune sera
elicited by the H5.tPA HA insert design but the exact mechanism
is currently unclear. First, we tested whether a higher level of HA
antigen expression was produced with the tPA-leader design. As
shown in Fig. 2A and 3A, antigen expression levels between WT-
leader design and tPA-leader design were similar, thus excluding
this possibility. Next, we asked whether there is increased secretion
of the HA antigen due to the use of the tPA leader. However, as
shown in Fig. 2A and 3A, there is no major detectable level of
secreted HA antigens in supernatant for either the WT-design or
tPA-design. Furthermore, the dTM design did have a higher level
of secretion due to the deletion of transmembrane and
intracellular portion of HA protein but did not elicit better
protective antibody responses. Finally, a study was conducted to
examine the possible role of post-translational processing, such as a
change in glycosylation, of HA the antigen, which may affect the
antigen processing pathway, as we previously reported with a
hepatitis B surface antigen DNA vaccine [33,34,35]. However,
Figure S1 showed that there is no major difference between WT-
design and tPA-design after de-glycosylation treatment.
Therefore, it is very likely that HA antigen expressed with the
tPA leader may be more effective in eliciting conformational
antibodies. This hypothesis is supported by two pieces of evidence.
First, there was no difference in the levels of binding antibodies as
Figure 6. Levels and specificity of anti-HA IgG (upper panel), HI
(middle panel), and NAb (lower panel) antibody responses
elicited by H5-VN (A/VietNam/1203/2004) and H5-AH (A/
Anhui/1/2005) HA DNA vaccines in rabbits immunized with
H5-VN-tPA (3 rabbits) and H5-AH-tPA (4 rabbits), respectively,
at two weeks after the 4
th DNA immunization. Peak serum level
anti-H5 HA IgG responses, as measured by ELISA against the H5-VN-
dTM or H5-AH-dTM antigens. HI antibody and NAb titers were detected
against H5N1 A/VietNam/1203/04 or A/Anhui/1/2005 virus, respectively.
Neutralizations against wild type H5N1 viruses were performed in
MDCK cells. Data shown are the geometric mean IgG, HI, or NAb titers
of each group with standard deviations. The statistical differences
between each testing groups are determined and P values less than
0.05 or 0.01 are indicated.
doi:10.1371/journal.pone.0028757.g006
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in the general immunogenicity between WT and tPA leader
designs; only a difference in the functional antibody was observed.
Second, the HA.dTM DNA vaccine design also used the tPA
leader but did not have better functional antibodies, proving that
the proper folding of the HA antigen in the presence of a tPA
leader is important and is dependent on the presence of an intact
HA2 domain. It is possible that such an HA antigen conformation
is part of a trimer structure of HA since the HA2 domain is
involved in the formation of HA trimers. Only antibodies against
the trimer structure are more functionally relevant to block the
trimer form of HA spikes on viral particles.
By using the optimal H5.tPA HA insert design, studies in this
report further demonstrated that there are good levels of cross
protection by one H5 HA DNA vaccine against multiple H5N1
viruses from different clades. It is well documented that cross
protection among H5N1 viruses can be detected [33,34,35]. Clade
1 H5N1 vaccines (VN) cross protect against both clade 1 and clade
2 (Indonesia) viruses in ferrets with the use of a strong adjuvant
[36]. Using live attenuated cold adapted (ca) viruses expressing HA
and NA from 1997, cross protection was observed against the late
H5 virus from 1997 to 2005 [37] and ferrets [37] and ferrets [38]
and mice [39,40] and mice [39,40].
However, as shown in the current study, not all H5 HA vaccines
can elicit the same levels of cross protective antibodies, and more
significantly, maximum levels of protective antibodies were usually
detected against the autologous viral isolates. Given the knowledge
that protective anti-flu antibody responses in humans are much
Figure 7. Levels and specificity of NAb responses against H5 pseudotyped viruses expressing full length H5 HA from A/VietNam/
1203/2004 (A/VN/1203/04-pv, Panel A), A/Anhui/1/2005 (A/AH/1/05-pv, Panel B) or A/Indonesia/5/2005 (A/Ind/5/05-pv, Panel C), by
different H5-HA DNA vaccines or empty DNA vector in rabbits. The vaccine group ‘‘HK’’, ‘‘VN’’, ‘‘AH’’ or ‘‘Ind’’ represent monovalent H5 DNA
vaccines HK.tPA, VN.tPA, AH.tPA, or Ind.tPA, respectively. The ‘‘3-valent’’ group consists of VN-HA.tPA AH-HA.tPA and Ind-HA.tPA H5 DNA vaccines.
There were 3 rabbits/group in Vector, HK, VN, AH, and Ind groups, and 4 rabbits/group in 3-valent groups. Rabbit sera tested by the pseudotyped
NAb assays were collected at 2 weeks after the 4
th DNA immunization. ‘‘,’’ denotes below detection level. The arrow denotes neutralization against
the autologous H5 pseudotyped virus. The statistical differences between the testing group and the autologous neutralization group or 3-valent
group are indicated by ‘‘*’’ when the p value was less than 0.05.
doi:10.1371/journal.pone.0028757.g007
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very high in humans with one randomly selected H5 HA vaccine.
In the current set of studies, it was encouraging to observe that the
polyvalent H5 HA DNA vaccine was able to elicit high level
protective antibody responses against multiple key H5N1 viruses.
Such a polyvalent flu DNA vaccine can be used for stockpiling
against a potential H5N1 pandemic even before information is
available on which viral isolates may cause a human outbreak. At
the same time, there are alternative approaches including the use
of consensus HA antigen designs to achieve a broad coverage of
various viral strains (personal communication with David Weiner).
It will be interesting to compare the relative efficacy between
polyvalent and consensus HA DNA vaccines in their abilities to
elicit protective antibody responses. One unique advantage of the
polyvalent formulation is its flexibility; one alternative HA antigen
can replace or be added to the earlier polyvalent formulation in
the event that a new strain of virus becomes a threat while it will
be necessary to re-design the whole consensus HA insert in order
to allow for broader coverage.
While HI titers against heterologous virus (cross-clade) were
significantly reduced compared to HI titers against homologous
virus in the current study, the heterologous virus titers were
generally above 1:100, and in humans, a HI titer of 1:40 has been
associated with protection [41], and so all of the constructs might
be protective after multiple immunizations. At the same time, the
titers observed in mice may not be the same as in humans. While
HI titers have been associated with protection, H5 HA DNA
vaccines described in the current report were not tested for
protection against challenge and so there is the possibility that only
some of these constructs may not protect against clinical disease or
lethal infection.
No matter the design of DNA vaccines that may be used, recent
studies have indicated that DNA priming immunization is effective
as part of the prime –boost strategy for flu vaccine applications. In
addition to DNA prime-inactivated flu vaccine boost [9,10], a
study published in 2011 further demonstrated that DNA prime-
live attenuated flu vaccine boost was equal to or more effective
than twice immunization with the live attenuated flu vaccine
against the H5N1 viruses based on antibody responses and viral
clearance in immunized ferrets [42]. Since live attenuated vaccines
are considered the most immunogenic form of vaccines, it is
impressive to observe that one time DNA prime was able to
achieve the same priming effect as a live attenuated flu vaccine. In
this particular study, the H5-VN.tPA DNA insert was used as part
of the collaboration with the manufacturer of live attenuated
H5N1 flu vaccine.
Based on the results published in the current report and other
recent similar studies, H5N1 HA DNA vaccines evaluated in the
current study should be included in the design of human studies to
understand whether results reported here can be reproduced
in humans when they are used as part of DNA prime, either
individually or as part of the polyvalent HA DNA formulation. The
finding from such studies will be very useful in the identification of
simple yet powerful approaches to develop vaccines against major
influenza pandemics.
Materials and Methods
Construction of codon optimized HA DNA vaccine
constructs
The codon usage of HA genes from influenza A H5N1 viruses
A/HongKong/156/97 (H5-HK), A/VietNam/1203/04 (H5-
VN), A/Anhui/1/2005 (H5-AH) and A/Indonesia/5/2005 (H5-
Ind) was analyzed with the MacVector software 7.2 against codon
preference of Homo sapiens. The less optimal codons in HA genes
were changed to the preferred codons in mammalian systems to
promote higher expression of the HA proteins, as previously
described [11]. These codon optimized HA genes were chemically
synthesized by Geneart (Regensburg, Germany) with added
restriction enzyme sites of PstI and BamHI for subcloning purpose
immediately upstream of the start codon and downstream of the
stop codon, respectively.
For either H5-HK or H5-VN HA DNA vaccines, three versions
of codon optimized HA gene inserts were cloned into DNA
vaccine vector pSW3891 [43]. For the first version, the full length
H5-HK or H5-VN HA gene insert (568 aa,) with their natural HA
leader sequences subcloned, individually, into the pSW3891 vector
at the PstI and BamHI sites, designated as H5-HK.wt or H5-
VN.wt DNA vaccine constructs. For the second version, the HA
natural leader sequence (the first 15 aa at N-terminus for both H5-
HK and H5-VN) was replaced by a human tissue plasminogen
activator (tPA) leader sequence. The H5-HK and H5-VN HA
gene inserts coding for aa 16–568 were PCR amplified from the
full length codon optimized H5 HA genes using the following
primers: H5-HA-opt-1 (gtcgctccgctagc GACCAGATCTGCATC-
GGCTAC) and H5-HA-opt-2 (agtcacggatcc TCAGATGCA-
GATCCGGCACTG). The individual H5-HK or H5-VN HA
gene was cloned into the pSW3891 vector at the NheI and BamHI
sites downstream of the tPA leader sequence and designated as
H5-HK.tPA or H5-VN.tPA DNA vaccine constructs. For the
third version, the HA natural leader sequence was replaced by a
tPA leader sequence and the transmembrane (TM) and cytoplas-
mic region (37 aa at the C-terminus) of H5 and HA was deleted
for both H5-HK and H5-VN. The truncated H5-HK or H5-VN
HA genes were PCR amplified from the full length codon
optimized H5-HK or H5-VN HA gene using primer pairs: H5-
HA-opt-1 and H5-HA-opt-4 (agtcac ggatccTCACTGGTAG-
GTGCCCATGCTCTC), or H5-HA-opt-1 and H5-HA-opt-8
(agtcacggatccTCACTGGTAGATGCCGATGCTTTC), respec-
tively. The truncated H5-HK or H5-VN gene insert was
individually cloned into the pSW3891 vector at the NheI and
BamHI sites downstream of the tPA leader sequence and
designated as H5-HK.dTM or H5-VN.dTM.
For the H5-AH HA DNA vaccine, the construct with the full
length HA under tPA-leader sequence was made as described
above. Each individual DNA vaccine plasmid was prepared from
Escherichia coli (HB101 strain) with a Mega purification kit (Qiagen,
Valencia, CA) for both in vitro transfection and in vivo animal
immunization studies.
DNA immunization of New Zealand White (NZW) rabbits
NZW rabbits (,2 kg body weight) were purchased from
Millbrook Breeding Labs (Amherst, MA) for immunogenicity
studies, and housed in the Department of Animal Medicine at the
University of Massachusetts Medical School in accordance with
IACUC approved protocol. The rabbits (3 rabbits/group) were
immunized with a Helios gene gun (Bio-Rad) at the shaved
abdominal skin as previously reported [44] with a total of 36 mg
H5 HA DNA vaccine plasmid or vector control plasmid at each
immunization. DNA immunizations were given at weeks 0, 2, 4, 8.
Serum samples were taken prior to the first immunization and 2
weeks after each immunization for study of H5 HA-specific
antibody responses.
Ethics statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of Laboratory
Animals of the National Institutes of Health. The protocol was
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Institutional Animal Use and Care Committee (IACUC) (Protocol:
A-1674). All surgery was performed under sodium pentobarbital
anaesthesia, and all efforts were made to minimize suffering.
Western blot analysis of in vitro expressed HA antigens
Transient expression of the HA antigens from various HA DNA
vaccine constructs were verified by Western blot analysis. HA DNA
vaccine constructs were first transfected into the human embryonic
kidney 293T cells using the calcium phosphate precipitation
method. Briefly, 2610
6 293T cells at 50% confluence in a 60 mm
dish were transfected with 10 mg of plasmid DNA, and a total of
3 ml supernatant and 100 ml of cell lysate were harvested 72 hours
later. Equal amounts of each transiently expressed HA antigen
(10 ng of protein in 10 ml) were loaded for the SDS-polyacrylamide
gel electrophoresis (SDS-PAGE) under denatured conditions, then
transferred onto PVDF membranes (Bio-Rad, Hercules, CA). After
being blocked overnight at 4uC in blocking buffer (0.2% I-block,
0.1% Tween-20 in 16PBS), the membranes were incubated with a
1:500 dilution of rabbit sera immunized with HA DNA vaccines for
30 min followed by washes. Then, the membranes were incubated
with alkaline phosphatase-conjugated goat anti-rabbit IgG at
1:5000 dilution for 30 min. Following washes, the signals were
detected using a chemiluminescence-based Western-Light Kit
(Tropix, Bedford, MA).
Deglycosylation of H5 HA antigens
To analyze the N-linked glycosylation of H5 HA antigens
expressed by various forms of H5 HA DNA vaccines, the HA
antigens expressed from 293T cells [45,46] were treated with
PNGaseF (New England BioLab, Beverly, MA) [47,48,49]. Briefly,
the HA proteins were first denatured at 100uC for 10 min in
glycoprotein denaturing buffer and then chilled on ice. Following
addition of G7 reaction buffer, the deglycosylation enzyme
cocktail was added and incubated reaction at 37uC for 4 hours.
Either mock-treated or deglycosylated HA samples were subjected
to SDS-PAGE and Western blot analysis was performed as
described above.
ELISA (Enzyme-linked immunosorbent assay)
ELISA was conducted to measure HA-specific antibody (IgG)
responses in immunized rabbits and mice. The 96-well flat-bottom
plates were coated with 100 ml of ConA (50 mg/ml) for 1 hour at
room temperature, and washed 5 times with PBS containing 0.1%
Triton X-100. Subsequently, the plates were incubated overnight
at 4uC with 100 ml of transiently expressed HA antigen at 1 mg/
ml. After being washed 5 times as above, the plates were then
blocked with 200 ml/well of blocking buffer (5% non-fat dry milk,
4% Whey, 0.5% Tween-20 in PBS at pH7.2) for 1 hour. After five
washes, 100 ml of serially diluted rabbit or mouse serum was added
in duplicate wells and incubated for 1 hour. After another set of
washes, the plates were incubated for 1 hour at 37uC with 100 ml
of biotinylated anti-rabbit or anti-mouse IgG (Vector Laborato-
ries, Burlingame, CA) diluted at 1:1000 in Whey dilution buffer
(4% Whey, 0.5% Tween-20 in PBS). Then, 100 ml of horseradish
peroxidase-conjugated streptavidin (Vector Laboratories) diluted
at 1:2000 in Whey buffer was added to each well and incubated
for 1 hour. After the final washing, the plates were developed with
3,39,5,59 Tetramethybenzidine (TMB) solution at 100 ml per well
(Sigma, St. Louis, MO) for 3.5 minutes. The reactions were
stopped by adding 25 mlo f2MH 2SO4, and the plates were read
at OD 450 nm. The end titration titer was determined as the
highest serum dilution that has an OD reading above twice of that
from the negative control serum.
Preparation of the influenza A viruses stocks
Influenza A viruses of the H5N1 A/HongKong/483/97 (H5N1),
A/Viet Nam/1203/04 (H5N1), A/Anhui/1/2005 (H5N1), and A/
Indonesia/5/2005 (H5N1) were grown in the allantoic cavity of 10-
day-old embryonated hen eggs at 37uC for 26 to 40 h. Allantoic
fluid pooled from multiple eggs was clarified by centrifugation and
frozen in aliquots at 270uC. The 50% egg infectious dose (EID50)
for each virus stock was calculated by the method of Reed and
Muench following serial titration in eggs. All experiments with
HPAI viruses were conducted under Biosafety Level 3 containment.
Hemagglutination-inhibition (HI) assay
HI assays were performed by standard methods [50]. Briefly,
the assay was performed using, 0.5% v/v fowl or horse [30] red
blood cells, 4 HA unit of reference H5N1 virus (A/HongKong/
483/97, A/VietNam/1203/04, A/Anhui/1/2005, A/Indonesia/
5/2005) and specific sera treated with receptor destroying enzyme.
The HI titer was defined as the highest dilution of the serum able
to inhibit hemagglutination.
Microneutralization (MN) assay
MN assays was performed as described previously [51]. In brief,
influenza virus containing 100 TCID50 was incubated with equal
volume of two-fold dilutions of the specific heat-inactivated serum
overnight at 37uC in a 5% CO2 humidified atmosphere for 1 hr.
After the incubation, 100 ml virus-serum samples were added to a
96-well plate containing Madin Darby Canine Kidney (MDCK)
cell monolayer and incubated for 5 days at 37uC and 5% CO2.
The microneutralization titer was defined as the highest dilution of
serum that neutralized 100 TCID50 of virus in MDCK cell [52,53]
cultures (as detected by the absence of cytopathic effects). The MN
assays were conducted in two different labs: 1) National
Microbiology Laboratory, Public Health Agency of Canada, and
2) Beijing Institute of Microbiology and Epidemiology, according
to the viruses available.
Pseudotyped virus (PV) assay
The recombinant lentiviral vectors expressing a luciferase
reporter gene were produced as previously described [28,54,55].
To produce H5N1 pseudotyped viruses, 293T cells [45,46] (5610
6
cells plated the day before) were transfected with 13.43 mg of pNL
4-3.Luc.R-E- (NIH AIDS reference and reagent program), 1.2 mg
of H5-HA-wt DNA vaccine plasmid and 0.3 mg of N1-NA plasmid
using 75 mg of polyetheleneimine transfection reagent. Superna-
tants were harvested 48 hours later, frozen at 280uC and then
standardized by infectivity in 293A cells using a luciferase-based
TCID50 measurement. For neutralization assays, serum samples
(5 ml) were heat inactivated at 56uC for 30 minutes, then three-
fold serially diluted in culture medium in flat-bottomed microtiter
plates. Pseudotyped H5N1 virions were then added to the plates at
200 TCID50/well and incubated for 1 hour at 37uC. After
incubation, 293A cells were trypsinized and added to each plate at
a dilution of 1610
4 cells per well. Following a 48-hour incubation,
plates were developed using a luciferase assay system (Promega).
Values averaged from triplicate wells were then used to determine
IC50 based on wells that displayed 50% reduction in infection as
compared to control wells containing virus plus pre-immune sera.
Supporting Information
Figure S1 Western blot analysis of potential N-linked
glycosylations of HA protein expressed by differently
designed H5-VN (A/VietNam/1204/04) DNA vaccines:
H5-VN.wt, H5-VN.tPA, H5-VN.dTM or empty vector,
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without (U) PNGase F treatment.
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